These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10023931)
21. 'Statistical controversies in clinical research': a new series in Annals of Oncology. Soria JC; Buyse M Ann Oncol; 2015 Aug; 26(8):1532. PubMed ID: 25904726 [No Abstract] [Full Text] [Related]
22. Drug trials in pediatric oncology: a multi-facetted problem. Boos J Int J Clin Pharmacol Ther; 1998 Nov; 36(11):613-20. PubMed ID: 9849753 [TBL] [Abstract][Full Text] [Related]
23. Are patient safeguards adequate? Hirshaut Y Cancer Invest; 1983; 1(2):195-6. PubMed ID: 6667404 [No Abstract] [Full Text] [Related]
24. Clinical trials in oncology: ethics, errors, methods and results. Proceedings of an international symposium. Villejuif, France, 25-29 June 1984. Drugs Exp Clin Res; 1986; 12(1-3):1-298. PubMed ID: 3732045 [No Abstract] [Full Text] [Related]
25. American Society of Clinical Oncology Developing First Clinical Trial. Brower V J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625 [No Abstract] [Full Text] [Related]
26. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations]. Hanauske AR Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122 [No Abstract] [Full Text] [Related]
27. On the nature and ethics of phase I clinical trials of cancer chemotherapies. Lipsett MB JAMA; 1982 Aug; 248(8):941-2. PubMed ID: 7097961 [TBL] [Abstract][Full Text] [Related]
28. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? Saad ED; Buyse M J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092 [No Abstract] [Full Text] [Related]
29. Clinical endpoints in trials of drugs for cancer: time for a rethink? Koopmans PP BMJ; 2002 Jun; 324(7350):1389-91. PubMed ID: 12052814 [No Abstract] [Full Text] [Related]
30. [Recent proposals for early stage clinical trials of cancer]. Ohashi Y Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106 [TBL] [Abstract][Full Text] [Related]
31. Introduction and commentary: Paving the way for biosimilars in oncology. Abraham J Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943 [No Abstract] [Full Text] [Related]
32. The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process. De Feo G; D'Ambrosio F; Palmieri G; Perrone F; Ciliberto G Tumori; 2015; 101 Suppl 1():S33-7. PubMed ID: 27096270 [TBL] [Abstract][Full Text] [Related]
33. The conduct of therapeutic trials in cancer medicine. Rudnick S; Capizzi RL Semin Oncol; 1977 Jun; 4(2):255-8. PubMed ID: 327556 [No Abstract] [Full Text] [Related]
34. The ethical approach to randomization in oncology. Arpaillange P; Dion S Drugs Exp Clin Res; 1986; 12(1-3):99-103. PubMed ID: 3732058 [No Abstract] [Full Text] [Related]
35. Novel trial designs for novel agents. Interview by Helen Saul. Simon R Eur J Cancer; 2008 Jan; 44(2):170-1. PubMed ID: 18335587 [No Abstract] [Full Text] [Related]
36. Research outcomes and recommendations for the assessment of progression in cancer clinical trials. Bushnell W; Stone A J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508 [No Abstract] [Full Text] [Related]
37. New Clinical Trial Designs Hasten Approvals for Targeted Therapies. Schmidt C J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760 [No Abstract] [Full Text] [Related]
39. Methodologic considerations for trials of lung cancer prophylaxis. Miller AB Can Med Assoc J; 1980 Apr; 122(7):776-9. PubMed ID: 7363245 [TBL] [Abstract][Full Text] [Related]